175 related articles for article (PubMed ID: 26640968)
1. An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection.
Wagner FF; Lundh M; Kaya T; McCarren P; Zhang YL; Chattopadhyay S; Gale JP; Galbo T; Fisher SL; Meier BC; Vetere A; Richardson S; Morgan NG; Christensen DP; Gilbert TJ; Hooker JM; Leroy M; Walpita D; Mandrup-Poulsen T; Wagner BK; Holson EB
ACS Chem Biol; 2016 Feb; 11(2):363-74. PubMed ID: 26640968
[TBL] [Abstract][Full Text] [Related]
2. Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes.
Dirice E; Ng RWS; Martinez R; Hu J; Wagner FF; Holson EB; Wagner BK; Kulkarni RN
J Biol Chem; 2017 Oct; 292(43):17598-17608. PubMed ID: 28860191
[TBL] [Abstract][Full Text] [Related]
3. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for the design and synthesis of selective HDAC inhibitors.
Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics.
Meier BC; Wagner BK
Epigenomics; 2014 Apr; 6(2):209-14. PubMed ID: 24811789
[TBL] [Abstract][Full Text] [Related]
6. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
7. Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors.
Whitehead L; Dobler MR; Radetich B; Zhu Y; Atadja PW; Claiborne T; Grob JE; McRiner A; Pancost MR; Patnaik A; Shao W; Shultz M; Tichkule R; Tommasi RA; Vash B; Wang P; Stams T
Bioorg Med Chem; 2011 Aug; 19(15):4626-34. PubMed ID: 21723733
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis.
Chou DH; Holson EB; Wagner FF; Tang AJ; Maglathlin RL; Lewis TA; Schreiber SL; Wagner BK
Chem Biol; 2012 Jun; 19(6):669-73. PubMed ID: 22726680
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children.
Lundh M; Christensen DP; Damgaard Nielsen M; Richardson SJ; Dahllöf MS; Skovgaard T; Berthelsen J; Dinarello CA; Stevenazzi A; Mascagni P; Grunnet LG; Morgan NG; Mandrup-Poulsen T
Diabetologia; 2012 Sep; 55(9):2421-31. PubMed ID: 22772764
[TBL] [Abstract][Full Text] [Related]
10. Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases.
Felice C; Lewis A; Armuzzi A; Lindsay JO; Silver A
Aliment Pharmacol Ther; 2015 Jan; 41(1):26-38. PubMed ID: 25367825
[TBL] [Abstract][Full Text] [Related]
11. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
Bürli RW; Luckhurst CA; Aziz O; Matthews KL; Yates D; Lyons KA; Beconi M; McAllister G; Breccia P; Stott AJ; Penrose SD; Wall M; Lamers M; Leonard P; Müller I; Richardson CM; Jarvis R; Stones L; Hughes S; Wishart G; Haughan AF; O'Connell C; Mead T; McNeil H; Vann J; Mangette J; Maillard M; Beaumont V; Munoz-Sanjuan I; Dominguez C
J Med Chem; 2013 Dec; 56(24):9934-54. PubMed ID: 24261862
[TBL] [Abstract][Full Text] [Related]
13. Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
Yoo J; Kim SJ; Son D; Seo H; Baek SY; Maeng CY; Lee C; Kim IS; Jung YH; Lee SM; Park HJ
Eur J Med Chem; 2016 Jun; 116():126-135. PubMed ID: 27060764
[TBL] [Abstract][Full Text] [Related]
14. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
Ganai SA
Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia.
Weïwer M; Lewis MC; Wagner FF; Holson EB
Future Med Chem; 2013 Sep; 5(13):1491-508. PubMed ID: 24024943
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
Lin X; Chen W; Qiu Z; Guo L; Zhu W; Li W; Wang Z; Zhang W; Zhang Z; Rong Y; Zhang M; Yu L; Zhong S; Zhao R; Wu X; Wong JC; Tang G
J Med Chem; 2015 Mar; 58(6):2809-20. PubMed ID: 25734520
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
Tashima T; Murata H; Kodama H
Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
[TBL] [Abstract][Full Text] [Related]
18. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
[TBL] [Abstract][Full Text] [Related]
19. The class I histone deacetylase inhibitor MS-275 prevents pancreatic beta cell death induced by palmitate.
Plaisance V; Rolland L; Gmyr V; Annicotte JS; Kerr-Conte J; Pattou F; Abderrahmani A
J Diabetes Res; 2014; 2014():195739. PubMed ID: 25610877
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
